The scaling phase of a wireless medical device program is where the capital bill accelerates. Once the engineering work is done, building clinical relationships, training hospital users, and converting initial placements into contracted revenue can consume more capital than the device development itself. Xenter, the Draper, Utah company operating the TechMed™ platform, closed a $58.25 million Series B on July 16, 2026, directing the proceeds at that specific phase.
XenFi and the TechMed stack
The announcement centers the raise on three areas: the commercial launch of XenFi™, continued innovation of wireless medical devices and technologies, and the AI-Enabled Physical Intelligence™ platform. All three are positioned as components of the TechMed™ system. The release does not allocate the $58.25 million across those areas or specify a launch date for XenFi™.
Physical Intelligence is Xenter's branded name for the AI layer within TechMed™. The term treats AI processing as integral to the company's wireless hardware. The release does not describe clinical applications or device-level specifications.
Capital stage and what it signals
For the reader tracking private medtech capital flows, a $58.25 million Series B at the point of commercial launch signals that Xenter is absorbing the full build-out cost of market entry. That phase requires field teams, clinical educators, and contracting infrastructure. How quickly XenFi™ converts clinical interest into recurring revenue will determine what runway this round actually buys.
Xenter's investor list and pre-money valuation are not disclosed in the announcement.
Board addition
Linda Vega, identified as a financial executive in the announcement, was appointed to Xenter's board of directors alongside the financing close. No prior institutional affiliation is listed in the release.